China International Capital Corp (CICC) plans to absorb two smaller brokerages to create a new entity worth 1 trillion yuan (US$140 billion) in assets, as a state-led consolidation gathers pace to meet Beijing's goal of creating investment banks that can compete with the likes of Goldman Sachs. CICC would take over Dongxing Securities and Cinda Securities through stock swaps with the shareholders of the two peers, it said in an exchange statement on Wednesday night, without giving details. Shares of the t ...

Core Viewpoint - The article discusses the optimistic outlook for China's economy and A-share market in 2026, highlighting the potential for high-quality development and the importance of sectors such as technology, cyclical industries, and manufacturing [3][5][11]. Economic Outlook - Multiple institutions predict that China's economy will maintain resilience and enter a new phase of high-quality development in 2026, marking the beginning of the "15th Five-Year Plan" [5]. - Macro policies are expected to shift from extraordinary counter-cyclical adjustments to a more normalized approach, focusing on technological self-reliance and the cultivation of new productive forces [5]. - External demand is anticipated to remain robust, while internal demand will rely on fiscal efforts to stimulate investment in human capital and consumer supply [5]. A-share Market Trends - The A-share market has been on a rising trend since 2025, with active trading observed. There are differing opinions on whether this upward trend will continue in 2026, with some institutions expecting a comprehensive market rally while others foresee a slowdown in growth [7][8]. - By mid-2026, it is expected that the "policy bottom, market bottom, and economic bottom" will successively appear, potentially triggering a comprehensive market rally [8]. - The overall sentiment is that the A-share market's upward momentum is far from over, with expectations that it may challenge levels not seen in the past decade [8]. Sector Focus - Key sectors to watch in 2026 include technology, cyclical industries, and manufacturing, with specific attention to areas such as AI, robotics, energy storage, photovoltaics, pharmaceuticals, and military industries [11]. - Institutions suggest that resource products may emerge as a new mainline direction following technology, driven by global monetary easing, supply-demand gaps, and domestic inventory replenishment [11]. - The TMT (Technology, Media, and Telecommunications) and advanced manufacturing sectors are expected to remain central to market dynamics, with potential for significant growth [11]. Capital Flow Insights - Residents are identified as the most significant source of funds in the A-share market, with current trends resembling those seen in 2015. High-risk preference funds have entered the market rapidly, while medium-risk preference funds may represent the next incremental growth phase [9].

格隆汇11月20日｜中信建投证券研报指出，中科曙光发布2025年三季度报告，业绩表现亮眼，收入稳健 增长，扣非净利润同比高增。公司近期发布scaleX640超节点，单机柜算力密度大幅提升，支持多品牌 加速卡及主流计算生态，有望构建国产智算新范式。公司与海光信息吸收合并事项积极推进中，目标打 造国产算力全产业链龙头，有望实现从芯片到服务的深度融合与协同，显著提升核心竞争力。维持"买 入"评级。 ...

Core Viewpoint - The shareholders of Jinkai Biological Science and Technology (金凯生科) plan to reduce their holdings, which may impact the stock's performance and investor sentiment [1][2][3] Shareholder Reduction Plans - Shareholder Qilu (Xiamen) Equity Investment Partnership plans to reduce up to 3,612,000 shares, accounting for 3% of the total share capital, with a breakdown of 1,204,000 shares through centralized bidding and 2,408,000 shares through block trading [1][2] - Shareholder Qingdao Qingsong Venture Capital Group plans to reduce up to 1,204,000 shares, representing 1% of the total share capital, through centralized bidding [1][2] - Shareholder Blue Economic Zone Industrial Investment Fund plans to reduce up to 2,339,076 shares, accounting for 1.94% of the total share capital, with 1,204,000 shares through centralized bidding and 1,135,076 shares through block trading [2] Total Reduction Overview - The total planned reduction by Qilu Investment, Qingsong Investment, and Blue Zone Fund amounts to 7,155,076 shares, which is 5.94% of the total share capital [2] Current Shareholding Structure - As of the announcement date, Qilu Investment holds 5,936,580 shares (4.93%), Qingsong Investment holds 3,861,074 shares (3.21%), and Blue Zone Fund holds 2,339,076 shares (1.94%) [2] Company Background - Jinkai Biological Science and Technology was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on August 3, 2023, with an issuance of 21,508,335 shares at a price of 56.56 RMB per share [3] - The company raised a total of 1.216 billion RMB, with a net amount of approximately 1.111 billion RMB after deducting issuance costs [3] - The company plans to use the raised funds for pharmaceutical intermediates, high-end pharmaceutical products, and working capital [3] Dividend Distribution Plan - The company plans to distribute dividends at a rate of 8 RMB per 10 shares and to increase capital by 4 shares for every 10 shares held, with the record date set for May 8, 2024 [3]

2025年11月17日，中国宏桥（1378.HK）完成定价15亿美元（116.8亿港元）先旧后新配售，本项目亦为 今年以来香港资本市场第三大规模的新股配售。中信建投证券作为联席全球协调人及配售代理，助力公 司顺利完成本次发行。 来源：市场资讯 （来源：中信建投证券投行委） 中国宏桥 中信建投证券 本次基础发行规模为12亿美元，簿记启动后获得国际和国内主权基金、顶级长线基金和多策略基金热烈 追捧，最终发行规模上调至15亿美元，充分印证了市场对中国宏桥投资价值的高度认可。 坚守金融服务实体经济的根本宗旨 中信建投证券坚守金融服务实体经济的根本宗旨，依托"行业+区域+产品"的矩阵服务模式，协助中国 宏桥及下属子公司完成了多个资本运作项目，强化我国在全球有色金属产业链中的重要地位，服务客户 不断提升创新力和竞争力，书写金融助力实体经济的新篇章。 全球领先的铝产品制造商 中国宏桥是一家全球特大型铝生产企业和全球领先的铝产品制造商。公司成功构建了铝土矿、氧化铝、 电解铝及铝深加工一体化铝产业链，形成了显著的抗风险能力、成本控制能力等核心竞争力，是全球少 数几家具有完整一体化铝产业链优势的综合性铝生产、制造和销售企业。 本 ...

Core Viewpoint - The investment outlook for the pharmaceutical and bioproducts industry in 2026 indicates a potential recovery in demand and improvement in fundamentals and valuations, particularly in the traditional Chinese medicine sector [1] Group 1: Traditional Chinese Medicine - Short-term pressure from the base is expected to ease, with channel inventory clearing accelerating [1] - There is optimism for demand recovery by the end of the year, along with opportunities for fundamental and valuation improvements [1] - The brand extension space for traditional Chinese medicine consumer companies is broad, supported by innovation [1] Group 2: Blood Products - Attention is drawn to the "14th Five-Year Plan" for plasma station construction and industry consolidation progress [1] - Demand for immunoglobulin and factor products is expected to increase, along with new product development [1] Group 3: Vaccine Industry - Focus on the sales improvement of key products and the progress of innovative pipelines [1] - Policy developments and international expansion of vaccines are anticipated to further drive corporate growth [1] Group 4: Pharmaceutical Retail - The transformation and reform in the pharmaceutical retail sector are progressing steadily [1] - Future catalysts for growth are being monitored [1] Group 5: Pharmaceutical Distribution - The revenue side of the pharmaceutical distribution industry is showing steady improvement [1] - Attention is on payment collection and the "14th Five-Year Plan" [1]

11月20日，多氟多跌5.02%，截至发稿，报36.11元/股，成交43.59亿元，换手率10.77%，总市值429.87 亿元。 资料显示，多氟多新材料股份有限公司位于河南省焦作市中站区焦克路，成立日期1999年12月21日，上 市日期2010年5月18日，公司主营业务涉及六氟磷酸锂及电子化学品、锂离子电池、新能源汽车、无机 氟化盐。主营业务收入构成为：新能源材料34.97%，氟基新材料30.39%，新能源电池25.30%，电子信 息材料5.55%，其他3.80%。 截至发稿，冷文鹏累计任职时间9年163天，现任基金资产总规模13.31亿元，任职期间最佳基金回报 236.32%， 任职期间最差基金回报-21.77%。 从基金十大重仓股角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 数据显示，中信建投基金旗下1只基金重仓多氟多。中信建投价值增长混合A（025231）三季度持有股 数105.77万股，占基金净值比例为2.56%，位居第九大重仓股。根据测算，今日浮亏损失 ...

港股中资券商股集体上涨，东方证券涨超4%，中信证券、光大证券、中国银河、申万宏源、中信建投 证券涨超3%。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不 对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担 全部责任。邮箱：news_center@staff.hexun.com 消息面上，中金公司等三大券商宣布重大资产重组。11月19日深夜，中国证券业突发重磅消息！汇金控 股的中金公司、东兴证券、信达证券三家券商同时宣布重大资产重组，三家券商将实现"三合一"，成为 中国又一个"券商航母"。随着中金合并东兴、信达后，业内券商的排序进一步发生变化，越来越多的总 资产超过万亿的航母级券商涌现 ，并使得当下的券商并购热度直追本世纪初的高峰时期。 ...

东吴证券表示，行业内的资源整合或将成为券商快速提升规模与综合实力的又一重要方式。大型券商通 过并购进一步补齐短板，巩固优势，中小券商通过外延并购有望弯道超车，快速做大，实现规模效应和 业务互补。 中信建投指出，证券行业当前配置价值提升的核心逻辑在于政策、资金及自身转型的三方面支撑。政策 端，"活跃资本市场"导向明确，注册制深化、交易机制优化、引入中长期资金等举措持续落地，直接拓 宽了券商投行、经纪、资管等业务空间。资金端，市场信心修复带动成交回暖与两融回升，叠加养老 金、保险等增量资金入市可期，为券商业绩提供弹性基础。自身转型方面，行业正着力发展高附加值业 务，尤其是财富管理和机构业务，优化收入结构并增强盈利稳定性。券商不仅受益于市场回暖的Beta弹 性，更因成功转型而具备独特的Alpha增长潜力（盈利质量提升）。政策预期、资金改善与内生动力共 同作用，使得券商板块的盈利前景确定性提升，当前具备较高的配置吸引力。 消息面上，11月19日晚，中金公司、东兴证券、信达证券发布《关于筹划重大资产重组的停牌公告》， 三家公司正在筹划由中金公司通过向东兴证券全体A股换股股东发行A股股票、向信达证券全体A股换 股股东发行 ...

疫苗：经营持续承压，期待销售环比改善及新品贡献 1)看好创新品种未来格局，建议关注创新疫苗管线研发进展。2)政策方面：近期商业保险、医防融合及 行业并购相关政策陆续出台，为疫苗行业未来发展奠定了政策基础，期待后续进展。3)疫苗行业出海： 随着疫苗企业出海事业持续推进，出海动作也在价值链上下游加速延展深化，期待各企业海外市场开拓 进展。4)国资入主持续赋能，关注后续进展。 医药零售：转型变革稳步推进，关注多元催化 智通财经APP获悉，中信建投发布研报称，中药行业短期基数压力有望缓解，渠道库存加速出清，看好 年底需求回暖，及后续基本面和估值改善机会;创新领域有助构建第二增长曲线，中药消费品公司品牌 延展空间广阔。血制品行业关注"十五五"浆站建设规划及行业并购整合进展，需求端看好静丙、因子类 产品需求端提升及新品研发。疫苗行业关注重磅产品销售改善情况及创新管线研发进展，政策出台及疫 苗出海有望推动企业进一步发展。医药零售行业转型变革稳步推进，关注后续多元催化。医药流通行业 收入端稳健向好，关注回款及"十五五"规划。 中信建投主要观点如下： 中药：着眼长期，静待改善 1)短期行业基数压力有望逐步缓解，渠道调整加速出清 ...